Medicine
Anthrasil 60 IU/35 mL injection
Anthrasil 60 IU/35 mL injection is a prescription medicine containing Anthrax immune globulin human for intravenous use, marketed by Emergent BioSolutions Canada, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store frozen at or below ≤-15°C (≤5°F) until required for use.
Key facts
- Active ingredient (INN)
- Anthrax immune globulin human
- Brand
- Anthrasil
- Strength
- 60 IU/35 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 7 vials
- Marketing authorisation holder
- Emergent BioSolutions Canada
- Manufacturer
- Emergent BioSolutions Canada
- Origin register
- US FDA, United States
- Storage
- Store frozen at or below ≤-15°C (≤5°F) until required for use.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3002.12Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 5 October 2015
- Identifiers
- RxCUI 1722406, 1722407DailyMed set ID 97cc9a89-6fe0-424e-82d1-0cf9d19444dbNDC 60492-0249Application BLA125562
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 7 vial in 1 carton / 35 mL in 1 vial | 60492-0249-2 | Emergent BioSolutions Canada | 5 October 2015 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Anthrax immune globulin human is a prescription medicine indicated for the treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs, among other approved uses. MedsAcross supplies Anthrax immune globulin human for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Anthrax immune globulin humanFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Anthrasil prescribing information (Emergent BioSolutions Canada) · U.S. National Library of Medicine, DailyMed
Need Anthrasil 60 IU/35 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.